Conotoxin Interactions with $\alpha_9\alpha_{10}$-nAChRs: Is the $\alpha_9\alpha_{10}$-Nicotinic Acetylcholine Receptor an Important Therapeutic Target for Pain Management?

Sarasa A. Mohammadi and MacDonald J. Christie *

Discipline of Pharmacology, the University of Sydney, Sydney, NSW 2006, Australia; E-Mail: sarasa.mohammadi@sydney.edu.au

* Author to whom correspondence should be addressed; E-Mail: mac.christie@sydney.edu.au; Tel.: +61-2-9351-2946; Fax: +61-2-9351-3868.

Academic Editor: Irina Vetter

Received: 17 August 2015 / Accepted: 18 September 2015 / Published: 28 September 2015

Abstract: The $\alpha_9\alpha_{10}$-nicotinic acetylcholine receptor (nAChR) has been implicated in pain and has been proposed to be a novel target for analgesics. However, the evidence to support the involvement of the $\alpha_9\alpha_{10}$-nAChR in pain is conflicted. This receptor was first implicated in pain with the characterisation of conotoxin Vc1.1, which is highly selective for $\alpha_9\alpha_{10}$-nAChRs and is an efficacious analgesic in chronic pain models with restorative capacities and no reported side effects. Numerous other analgesic conotoxin and non-conotoxin molecules have been subsequently characterised that also inhibit $\alpha_9\alpha_{10}$-nAChRs. However, there is evidence that $\alpha_9\alpha_{10}$-nAChR inhibition is neither necessary nor sufficient for analgesia. $\alpha_9\alpha_{10}$-nAChR-inhibiting analogues of Vc1.1 have no analgesic effects. Genetically-modified $\alpha_9$-nAChR knockout mice have a phenotype that is markedly different from the analgesic profile of Vc1.1 and similar conotoxins, suggesting that the conotoxin effects are largely independent of $\alpha_9\alpha_{10}$-nAChRs. Furthermore, an alternative mechanism of analgesia by Vc1.1 and other similar conotoxins involving non-canonical coupling of GABA$_B$ receptors to voltage-gated calcium channels is known. Additional incongruities regarding $\alpha_9\alpha_{10}$-nAChRs in analgesia are discussed. A more comprehensive characterisation of the role of $\alpha_9\alpha_{10}$-nAChRs in pain is crucial for understanding the analgesic action of conotoxins and for improved drug design.

Keywords: $\alpha$-conotoxins; $\alpha_9\alpha_{10}$-nicotinic acetylcholine receptors; pain
1. Introduction

Pain is the emotional and sensory response to actual or potential tissue damage [1] and is vital for avoiding harm and for preventing further damage when recuperating from injury. In cases of chronic diseases or poor recovery from injury, this subjective pain experience becomes persistent. This transition from acute to chronic pain is incompletely understood, involving complex central nervous system (CNS) alterations, known as central sensitisation, that lead to pain hypersensitivity.

Chronic pain has conservatively been estimated to have a global prevalence of 22% [2]. Such estimates are likely to be underestimates due to the traditional view of pain as a secondary symptom to a primary disease; thus, primary diagnoses of pain are rare [3]. The common physiological and anatomical changes that occur in chronic pain sufferers have prompted some to argue for chronic pain to be considered as a disease entity in its own right [4,5]. In addition to the emotional and physical impact of chronic pain, the global economic burden is estimated to be in the hundreds of billions of dollars annually; a summation of costs to patients, carers, healthcare systems and the economy [3,5].

Currently available analgesics act via a limited number of molecular mechanisms. Chronic pain and neuropathic pain, which results from nerve injury or disease, are notoriously refractory to these pharmacological treatments. For mild to moderate pain, non-opioid analgesics, such as COX-inhibitors, are the primary means of treatment. However, these are inadequate in treating many neuropathic and chronic pain conditions and suffer from both ceiling effects and unfavourable side effect profiles [6]. Opiates are the most effective analgesics for acute pain, but are less effective for chronic neuropathic pain and are associated with significant adverse, dose-limiting side effects. Pregabalin and gabapentin were developed as anticonvulsants, but are now the first line treatment for some neuropathic pain conditions [7,8]. These drugs have high withdrawal rates due to the high risk of adverse events and are effective only in a minority of patients [8].

The narrow mechanistic range of current analgesic treatments can cause a patient’s treatment options to be rapidly exhausted, and patients are often left to endure chronic pain with only limited relief. Thus, in order to offer a broader range of treatment options to pain sufferers, new targets are being studied, including ion channels (e.g., calcium [9] and sodium channels [10]), transduction molecules (e.g., transient receptor potential (TRP) proteins [11–13]) and nicotinic acetylcholine receptors (nAChRs). Of great value to the study of such targets are conotoxins.

Conotoxins are peptides from the venoms of marine cone snails. Many conotoxins exhibit inherent selectivity and potency at mammalian cellular proteins, such as those involved in pain, and can therefore be used to better characterise those targets, while also holding potential as novel therapeutics themselves [14]. Heterogeneity in the subunit composition of certain ion channels, such as N-type calcium channels [15,16], sodium channels [17] and nAChRs [18], produces extensive structural diversity, which is recognised by many conotoxins. Thus, conotoxins offer great appeal as prospective selective therapeutics, with the potential of minimising off-target side effects.

Conotoxin peptides are classed according to their structure and respective ion channel or receptor target. Numerous conotoxin classes act on pain targets. Those classes of interest as potential analgesics include μ- and μO-conotoxins, which target voltage-gated sodium channels, ω-conotoxins, which target voltage-gated calcium channels, and α-conotoxins, which target nAChRs [19,20]. This review focuses
on nAChR-mediated mechanisms of pain and the potential mechanisms of pain relief produced by α-conotoxins that interact with α9α10-nAChRs.

2. nAChRs Involved in Pain

Nicotinic acetylcholine receptors (nAChRs) belong to the ligand-gated ion channel superfamily, which also includes GABA\textsubscript{A}, GABA\textsubscript{C}, glycine and 5-HT\textsubscript{3} receptors [21]. Human neuronal-type nAChRs exhibit a highly diverse composition of homo- or hetero-pentamers. Receptors are comprised of various combinations and permutations of alpha (α2-α7, α9, α10) and beta (β2-β4) subunits. Heteromers of α and β subunits are most abundant, while α7 is the only subunit known to form functional homomers. α8 and α9 subunits have been shown to form homomers in heterologous expression systems [22,23], but not in native systems.

nAChRs have long been the target of analgesic research, with little success. nAChR agonists, such as nicotine and epibatidine produce analgesia, but have small therapeutic windows and prohibitive side effect liabilities owing to their lack of selectivity [24,25]. Attempts to isolate the subunits responsible for nicotinic analgesia have identified α4β2- and α7-subunit-containing receptors; however, these subunits are not exclusively responsible for nicotinic analgesia [26]. Additional subunits, such as α3, α5 and β3, are believed to comprise part of the nicotinic analgesic effect [27–29].

The main factor that has limited the success of nAChR ligands is their narrow therapeutic window, i.e., inadequate clinical efficacy and/or high incidence of adverse events [30,31]. Since cholinergic communication and regulation is so ubiquitous in the mammalian system and the complexity of nAChRs so great, therapeutic nAChR ligands continue to pose a great challenge.

3. α-Conotoxins and Pain

All Conus species studied thus far contain a unique combination of α-conotoxins that act as nAChR ligands that are selective for neuronal-type over muscle-type receptors and that are subunit selective. α-Conotoxins usually act as competitive antagonists [32,33], although the novel conotoxin, MrIC from Conus marmoreus, which has no agonist activity itself, acts as a co-agonist with the positive allosteric modulator, PNU120596, at the endogenous α7-nAChR [34]. The therapeutic potential of this novel agonistic action of an α-conotoxin has not been explored. α-Conotoxins are small peptides, 12–19 amino acids in length, and are identified by their conserved CC-C-C cysteine pattern. These cysteines form two disulphide bonds with I–III, II–IV connectivity, resulting in a two-loop framework, with varying numbers of residues within each loop ([35]; see Table 1).

Although several hundreds of α-conotoxins are expressed by Conus species [36], the potential pain-relieving actions of less than ten have been characterized in any detail. Some of the most promising analgesic conotoxins to be studied to date are Vc1.1 and RgIA. Both of these peptides exhibit the characteristic cysteine pattern of α-conotoxins and are antagonists at nAChRs. Early publications suggested that Vc1.1 interacted with nAChRs containing the α3 subunit with either β2 or β4; however, the affinity at these subunits was too weak to account for its analgesic effects with IC\textsubscript{50} of 4200 and 7300 nM, respectively, at α3β2 and α3β4 recombinant rat nAChRs [37]. Vc1.1 was subsequently found to most selectively inhibit the α9α10-nAChR, with nanomolar affinity (19 nM at recombinant rat nAChRs [38]). This high functional selectivity for the α9α10-nAChR may overcome the classical challenges for
nAChR-therapeutics, wherein functional potency does not necessarily reflect the binding affinities of nAChR inhibitors [31,37]. Interestingly, both Vc1.1 and RgIA selectively inhibit the α9α10-nAChR [38,39], which is an evolutionarily divergent nAChR subtype, believed to be most similar to ancestral forms of nAChRs [32]. As with all peptide drugs, α-conotoxins face concerns of low stability and poor bioavailability, which limits their therapeutic potential. Efforts to increase both resistance to enzymatic degradation and structural stability of α-conotoxins have resulted in the successful backbone cyclisation of both Vc1.1 [40] and RgIA [41], increasing their oral bioavailability. Dicarba analogues of Vc1.1 [42] and RgIA [43] have also shown improved stability, as well as enhancing selectivity for their proposed analgesic targets. In silico studies have further elucidated the binding properties of RgIA at the α9α10-nAChR [44].

Table 1. Analgesic α-conotoxins with proposed dual mechanisms of action.

| Snail       | Conotoxin          | Sequence                        | Target                     | Analgesic? |
|-------------|--------------------|---------------------------------|----------------------------|------------|
|             | Vc1.1              | Conus victoriae                 | GCCSDPRCNYDHPEIC*         | Yes        |
|             | RgIA               | Conus Regius                    | GCCSDPRCR                  | Yes        |
|             | PeIA               | Conus pergrandis                | GCCSHPACSVNHPELC*         | Not tested |
|             | AuIB               | Conus aulicus                   | GCCSYPPCFATNPD-C*         | Yes        |

* Amidated C-terminus. Lines linking the cysteine (C) residues in the conotoxin sequences represent disulphide bonds that contribute to the structural stability. VGCC, voltage-gated calcium channel. Images reproduced with permission © 2015 Guido and Philippe Poppe: www.conchology.be (accessed on 20 August 2015).

The α9α10-nAChR has very limited tissue distribution, with no known CNS expression or peripheral nervous system protein expression [22,45–47], but has a significant role in the cochlea and auditory system [22,48,49]. α-Conotoxins Vc1.1 and RgIA are highly effective analgesics in animal models of chronic pain [50], and this has implicated the α9α10-nAChR in pain for the first time. Although Vc1.1 began development for clinical use, it was dropped during phase IIa of clinical trials after its potency at human α9α10-nAChRs was found to be 100-fold lower than at rat α9α10-nAChRs [51]. This large inter-species difference in potency at the putative mechanistic target was deemed cost prohibitive (notified to the Australian Stock Exchange by Metabolic Pharmaceuticals Limited in 2007, [52]), and alternative α9α10-nAChR inhibitors continue to be sought.
The availability of \( \alpha_9 \alpha_{10}-nAChR \)-selective conotoxins has been promoted as a bolster for pain-related research [32,53]. However, as discussed below, the precise role of the \( \alpha_9 \alpha_{10}-nAChR \) in pain is now known to be complex, and the mechanism of action(s) of these analgesic \( \alpha \)-conotoxins is not completely understood. Moreover, an alternative mechanism of action (discussed in Section 7) may account for many of the reported effects of Vc1.1 and RgIA. This alternative mechanism is likely shared by numerous other known conotoxins, such as PeIA and AuIB (Table 1), which may constitute a novel class of analgesics [54].

4. Evidence for \( \alpha_9 \alpha_{10}-nAChR \)-Inhibition for Analgesia

As discussed below, the evidence to support the involvement of \( \alpha_9 \alpha_{10}-nAChRs \) in pain comes solely from \textit{in vivo} pharmacological studies.

4.1. Analgesic \( \alpha \)-Conotoxins

Vc1.1 and RgIA have shown excellent analgesia in multiple rat models of chronic neuropathic pain. Intramuscular (i.m.) injection of these conotoxins has been shown to alleviate mechanical hyperalgesia [38,50,55] and mechanical allodynia [55–57] in models of chronic constriction injury (CCI) and partial nerve ligation (PNL) of the sciatic nerve. Intrathecal injection of Vc1.1 has also been shown to alleviate PNL-induced mechanical allodynia [58]. A cyclised version of Vc1.1 (cVc1.1) has shown anti-allodynic efficacy in CCI-induced neupathic pain after oral administration [40]. Independent testing of Vc1.1 by Metabolic Pharmaceuticals Pty. Ltd. (now a subsidiary of PolyNovo Ltd, formerly Calzada Ltd, Melbourne, Australia) confirmed the anti-allodynic and anti-hyperalgesic effects of i.m. Vc1.1 in the PNL and CCI models, as well as observing analgesic efficacy of Vc1.1 in pain associated with diabetic neuropathy (streptozotocin model) and inflammatory pain (at the highest doses only; complete Freund’s adjuvant (CFA) model) (previously posted in the Metabolic Pharmaceuticals Limited information sheet as cited in [59]).

In addition to acute analgesia, Vc1.1 has been shown to have long-acting effects that last well after the peptide has cleared. Repeated daily dosing of Vc1.1 for seven days has cumulative effects, with analgesia persisting for at least one week after the cessation of treatment [50,60].

4.2. Functional Recovery

Vc1.1 has been reported to accelerate the functional recovery of injured peripheral nerves. Satkunanathan \textit{et al.} [50] examined CCI-injured rats that had been treated for seven days with Vc1.1 during the course of neuropathic pain development, but had ceased conotoxin treatment approximately six weeks prior to functional testing. Blisters were raised on the glabrous skin of the injured hind limbs, and the peripheral vascular responses were monitored with laser Doppler flowmetry. When substance P, a potent vasodilator, was perfused over the blister in injured animals, the Vc1.1-treated animals exhibited a vascular response significantly closer to uninjured rats than the saline-treated animals. The relatively normal inflammatory vascular response to substance P in the Vc1.1-treated animals suggests that there was functional recovery in the previously injured nerves of the conotoxin-treated rats.
In a similar blister-induction model observing peripheral vascular responses, Sandall et al. [61] applied antidromic electrical stimulation of C-fibres in naive rats. Electrical stimulation of C-fibres induces vasodilation of the microvasculature in the blistered region. This was dose-dependently inhibited by Vc1.1 perfusion over the blister; thus, the peptide was postulated to act by reducing peripheral neurotransmitter release from the stimulated nociceptive C-fibres.

Whether the functional recovery observed in the Vc1.1-treated animals [50] and the acute Vc1.1-mediated inhibition of C-fibre neurotransmitter release [61] occur via the same mechanism is unknown. The unmodified, native form of the Vc1.1 peptide, Vc1.1ptm (also referred to as vc1a), similarly accelerates functional recovery [60] without producing significant analgesia [56,60]. This suggests that the functional recovery seen in α-conotoxin-treated animals may occur via mechanisms independent of the analgesic mechanisms. Whether these are α9α10-nAChR dependent is not known.

Histological changes in Vc1.1- and RgIA-treated animals have also been observed, wherein CCI-injured rats that are treated with these analgesic conotoxins show reductions in immune responses and injury markers. Vincler et al. [38] observed significant reductions in the infiltration of injured sciatic nerves by immune cells (CD2+ T-lymphocytes, CD68+ macrophages) and choline acetyltransferase positive (ChAT+) cells in Vc1.1 and RgIA-treated rats. More detailed histological investigations have revealed apparently neuroprotective effects of RgIA. Mannelli et al. [55] observed that after 14 days of daily RgIA administration, the number of fibres, myelin thickness, axon diameter, oedema, infiltrate, CD86+ and GFAP+ cells, nucleolus changes and glial cell changes are all significantly closer to those of sham animals than in injured, vehicle-treated animals. These effects were attributed to α9α10-nAChR inhibition. However, similar changes have not been observed in α9-nAChR knockout mice [62], suggesting that the conotoxin-mediated effects may be unrelated to inhibition of α9α10-nAChRs.

4.3. Side Effects

Analgesic α-conotoxins show promise as a novel class of analgesics that avoid many problematic adverse events that are associated with current analgesics, such as opiates. To date, no negative side effects have been reported in peer-reviewed publications after treatment with analgesic α9α10-inhibiting conotoxins, such as Vc1.1, RgIA and AuIB [63]. Metabolic Pharmaceuticals Pty. Ltd. performed safety profile analyses on Vc1.1 and found no effect on bodyweight, food consumption, ophthalmic parameters, haematology, blood chemistry, urinalysis, organ weights, macropathology, histopathology and no detectable immune response at any dose level in rats and mini-pigs. No motor effects (rat and mouse; Irwin test battery, accelerating rotarod) or respiratory effects (whole body plethysmography) were observed. Some cardiovascular effects were found at higher doses (dog telemetry; increased heart rate, decreased blood pressure) (previously posted in the Metabolic Pharmaceuticals Limited information sheet as cited in [59]).

Furthermore, no apparent tolerance has been observed with repeated dosing of Vc1.1; rather, there is a cumulative analgesic effect (Satkunanathan et al. [50], dose for seven days, test one week after final dose; Vincler et al. [38], dose for four days). Lack of tolerance suggests a useful alternative to opioid analgesics that are known to produce considerable tolerance with chronic treatment.
4.4. Non-Peptide, Small-Molecule $\alpha_9\alpha_{10}$-nAChR Inhibitors

Recently, several non-peptide, small-molecule $\alpha_9\alpha_{10}$-nAChR antagonists have been reported that have analgesic effects [64,65]. These compounds add further support to the possibility of an involvement of the $\alpha_9\alpha_{10}$-nAChR in pain. The quaternary ammonium analogues of nicotine were reported to achieve specific pharmacological block of the $\alpha_9\alpha_{10}$-nAChR. These compounds were found to be effective at attenuating the development of vincristine-induced, neuropathic pain (von Frey and paw pressure vocalisation threshold) and phase II formalin pain, as well as acutely relieving CCI and vincristine pain (paw pressure vocalisation threshold) at high doses [64,65].

However, as with the $\alpha$-conotoxin studies, these assertions are only as reliable as the selectivity, pharmacokinetics and pharmacodynamics of the compounds used. One non-peptide small molecule, ZZ-204G [64], caused motor incoordination (rotarod) as a side effect at high doses, which has been shown not to occur in $\alpha$-conotoxin studies (Metabolic Pharmaceuticals info sheet, as cited in [59]). This indicates that ZZ-204G also acts at non-$\alpha_9\alpha_{10}$-nAChR sites. Although these small-molecule nicotine analogues have been designed with high selectivity for the $\alpha_9\alpha_{10}$-nAChR, interactions with less common nAChR subunits or non-nAChR proteins is a possibility. Given the apparent lack of specificity, these nicotine analogues are unlikely to elucidate the role of $\alpha_9\alpha_{10}$-nAChRs in the in vivo context.

The dependence on pharmacological agents to characterize the functional role of receptor subtypes carries a significant risk of unknown functions of such compounds being misattributed to the known targets.

5. Evidence against $\alpha_9\alpha_{10}$-nAChR-Inhibition for Analgesia

Despite the promising results of the $\alpha$-conotoxin studies, the mechanism behind the analgesic actions of $\alpha$-conotoxins, such as Vc1.1 and RgIA, has not been confirmed. Assertions that the inhibition of $\alpha_9\alpha_{10}$-nAChRs is the mechanism of analgesia of these conotoxins are supported only by indirect evidence, and there is now sufficient evidence to rule out $\alpha_9\alpha_{10}$-nAChR inhibition as the primary analgesic mechanism of $\alpha$-conotoxins. The analgesic activity of $\alpha_9\alpha_{10}$-nAChR-selective drugs is summarised in Table 2.

5.1. Vc1.1 Analogue and Native Peptide

Pharmacological evidence for the insufficiency of $\alpha_9\alpha_{10}$-nAChR inhibition for analgesia was first shown by Nevin et al. [56]. The authors showed that the native peptide and an analogue of Vc1.1 that both retained their potency at and selectivity for $\alpha_9\alpha_{10}$-nAChRs produced no analgesia (von Frey threshold) in the PNL model of neuropathic pain in rats. The native peptide, vc1a, and the analogue [P6O]Vc1.1, were structurally almost identical to Vc1.1 apart from one (for [P6O]Vc1.1) or two (for vc1a) post-translational modifications (PTMs), indicating that any differences in biological targets were not due to major changes in the 3D shape of the molecules. The inability of the modified Vc1.1 peptides to alleviate pain, despite their equipotency with Vc1.1 at the $\alpha_9\alpha_{10}$-nAChR, clearly indicates the insufficiency of $\alpha_9\alpha_{10}$-nAChR inhibition for analgesia.
5.2. α9-nAChR KO Phenotype

Behavioural phenotyping of mice that have a germline deletion of the α9-nAChR have recently uncovered a unique pain phenotype that is starkly mismatched with α-conotoxin analgesic effects. α9-nAChR knockout (KO) mice were found to have a largely normal pain phenotype with only a single pain modality showing alteration from wild-type (WT) animals [59]. Naive KO mice showed completely normal nociceptive responses in all pain modalities tested, including the von Frey test, paw pressure test, hotplate test and acetone test. Pain models of neuropathic (CCI) and inflammatory (CFA) pain revealed a normal phenotype with respect to most pain modalities, including mechanical allodynia (von Frey threshold), thermal hyperalgesia and cold allodynia. An altered pain phenotype was, however, observed for mechanical hyperalgesia. Both the development and maintenance of chronic mechanical hyperalgesia were attenuated in KO mice. This pain phenotype does not mirror the anti-allodynic effects that are seen in conotoxin analgesia, indicating that at least part of the analgesic effects of α-conotoxins occur via non-α9α10-nAChR mechanisms.

Table 2. Summary of the in vivo analgesic activity of α9α10-nAChR-selective drugs.

| Compound Name | Analgesic? | Nerve Injury (PNL or CCI) | Formalin | Vincristine | Side Effects? | Functional Recovery? | References |
|---------------|------------|---------------------------|----------|-------------|---------------|----------------------|------------|
|               |            | Von Frey | R-S | Incap. |               | Sexual Effects |                     | References |
| Vc1.1         | Yes | Yes | - | - | - | No | Yes | [38,50,56–60] |
| RglIA         | Yes | Yes | Yes | - | - | N/R | - | [38,55] |
| vc1a          | No | - | - | - | - | N/R | Yes | [56,60] |
| [P60]Vc1.1    | No | - | - | - | - | N/R | - | [56] |
| cVc1.1        | Yes | - | - | - | - | N/R | - | [40] |
| ZZ-204G       | - | Yes | - | Yes | - | Yes | - | [64] |
| ZZ1-61c       | - | - | - | - | Yes | No | - | [65] |

All in vivo testing was performed in rats. Dashes indicate where no testing has been reported. CCI, chronic constriction injury; Incap., incapacitance test; N/R, none reported; PNL, partial nerve ligation; R-S, Randall-Selitto test.

6. The Site(s) of Action of α9α10-nAChR Inhibiting Analgesics is Unknown

6.1. Immune Cells

The putative mechanism of analgesia of α9α10-nAChR antagonists is through inhibition of immune cells [38,55] (Figure 1B). Support for this comes from the finding that repeated Vc1.1 or RglIA administration in rats significantly inhibited the migration of ChAT-immunoreactive cells, ED1-immunoreactive macrophages and CD2-immunoreactive T-cells into CCI injured nerves [38]. The high degree of selectivity of these conotoxins for α9α10-nAChRs was inferred to be the mechanism of action of both the inhibition of immune cell infiltration and the analgesia. The authors suggested that inhibition of α9α10-nAChRs on immune cells in the vicinity of nerve injury reduces the inflammatory milieu, thus reducing the overall algogenic pathology. However, similar suppression of immune reactions to neuropathic injury models are not seen in α9-nAChR KO mice [62], suggesting that the α-conotoxin-mediated effects seen by Vincler et al. [38] and Mannelli et al. [55] are not α9α10-nAChR-dependent effects.
Peripheral immune cells do express the main components of cholinergic communication, including nAChRs, choline acetyltransferase (ChAT) and ACh [66–68], so they could feasibly be targets for nicotinic analgesics. However, the presence of functional, ACh-responsive α9α10-nAChRs on immune cells is yet to be confirmed, and as yet, attempts to elicit α9α10-mediated ACh responses have not succeeded in either human B- or T-lymphocytes or Jurkat immortalised T-cells [69].

**Figure 1.** Proposed sites of action of analgesic α-conotoxins, such as Vc1.1. (A) Neuronal sites on peripheral sensory nerves (green) have been proposed, inhibiting (red Xs) either peripheral or central terminals. Central cholinergic neurons (yellow) are an ACh source. (B) Immune cell sites have been proposed. Scissors represent the sites of injury along the sensory afferent nerves.

There is therefore little doubt that Vc1.1 and Rg1A (and perhaps Vc1a) inhibit the invasion of immune cells into injured nerves, and this may mediate some of their analgesic and recuperative effects. However, the proposal that inhibition of α9α10-nAChRs on these cells is the mechanism underlying this action is questionable.

### 6.2. Neuronal Cells

Another potential site of action of systemically-acting analgesics is the peripheral sensory nervous system (Figure 1A). Unfortunately, no functional expression of α9α10-nAChRs has been shown on sensory afferent nerve axons, terminals or cell soma. The cell bodies of peripheral sensory nerves, collectively situated in the dorsal root ganglia (DRGs), do indeed express multiple nAChR subtypes [70], though these are predominantly α4 and α7 [46,70]. α9-nAChR mRNA expression has been inconsistently found in rat DRG neurons; however, no translated functional protein has been detected [45–47]. Putting this mechanism of action into further doubt is the fact that nAChRs have been shown to be downregulated in peripheral sensory afferents in neuropathic pain models [71], and *in vivo* studies show that α-bungarotoxin (α-BGTx)-sensitive nAChR subtypes (*i.e.*, α7 and α9) are minimally involved in nicotinic analgesia [72]. Therefore, inhibition of α9α10-nAChRs on peripheral nerves is very unlikely to explain the analgesic actions of the α-conotoxins.
Studies that have investigated the action of conotoxins on peripheral nerve cells have generally tested responses in dissociated DRG cell bodies. In many of these studies, the tissue preparation process uses enzymatic dissociation processes that may render the α9α10-nAChR inactive. Collagenase, the primary digestive enzyme used, uncouples the α9α10-nAChR from small conductance Ca²⁺-dependent K⁺ channel (SK2), which is a complex that has been shown to be necessary for α9α10-nAChR receptor function [73,74]. However, it is possible that the requirement of α9α10-nAChR/SK2 coupling is specific to the cochlear and vestibular hair cell types, in which this phenomenon was characterized, as functional α9α10-nAChRs have been recombinantly expressed in X. laevis oocytes [37,38,40,56,58,75].

6.3. Acetylcholine Source

For peripherally-acting analgesic α-conotoxins to act via nAChR inhibition, an intrinsic ACh source must be present at injury sites. A peripheral origin of a cholinergic plexus has been suggested that could account for nAChR activation, but the evidence is conflicted. Both the absence [76] and presence [77] of ChAT-immunoreactive DRG cells have been reported with the same antibody. The functional role of ACh in peripheral sensory neurons is speculated to be central inhibition of pain [77], though more evidence is needed to support this theory. A sub-group of nociceptors (capsaicin-sensitive) do not release ACh centrally [78]. Whether other sub-groups of nociceptive fibres do release ACh centrally remains to be determined.

Non-neuronal ACh sources include keratinocytes after cutaneous injury [79], as well as immune cells. A cutaneous source would not account for the pain relief attained by Vc1.1 in animal models, which involve nerve injury (CCI, PNL [38,40,50,56,57]), inflammatory (CFA) and chemogenic (diabetic neuropathy via streptozotocin injection pain). Immune cells, such as lymphocytes, dendritic cells and macrophages, express cholinergic components sufficient to constitute a discrete cholinergic system, synthesising and releasing ACh that has either an autocrine or paracrine effect [66,80]. Whether or not ACh released from immune cells does activate sensory afferent nerve nAChRs is unknown. It is possible that the main function of such ACh sources is activation of immune cell nAChRs, as nAChRs mRNA has been identified in thymocytes (α3, α5, β4 [81]) and lymphocytes (α2, α5, α6, α7, α10, β2 [82]). α9α10-nAChR protein has been identified in B- and T-cells; however, these receptors were unresponsive to applied ACh [69].

7. An Alternative Mechanism of α-Conotoxin Analgesia Is Known

An alternative mechanism of action of α-conotoxin analgesia that does not involve nAChRs has been identified. α-Conotoxins, such as Vc1.1 and RgIA, potently and selectively inhibit the N-type component of high-voltage-activated (HVA) calcium channel currents in dissociated DRG neurons. This inhibition of N-type VGCC is dependent on GABABR binding and completely independent of α9α10-nAChRs, but occurs via a non-canonical G-protein-mediated mechanism [45,83] (Figure 2). Inhibition of peripheral sensory nerve N-type VGCCs is thus believed to confer α-conotoxin analgesia via preventing the transmission of nociceptive input from the periphery to higher order centres. Further support for the GABABR-dependent VGCC inhibition being the primary analgesic mechanism of α-conotoxins is the finding that Vc1.1-analogues that retain the α9α10-nAChR inhibitory properties, but not the VGCC inhibition [45], do not alleviate pain in animal models [56]. The importance of GABABR
binding for α-conotoxin analgesia has been confirmed \textit{in vivo} through the co-administration of a GABA\textsubscript{B}R antagonist with Vc1.1 in rats, which completely abolished Vc1.1 analgesia [57].

\textbf{Figure 2.} Putative mechanisms of action of VGCC-inhibiting conotoxins. α-Conotoxins (α-CTX), such as Vc1.1, are thought to bind to GABA\textsubscript{B} receptors, which are coupled to \textit{N}-type Ca\textsuperscript{2+} channels. Conotoxin binding indirectly prevents Ca\textsuperscript{2+} entry through these Ca\textsuperscript{2+} channels. ω-Conotoxins (ω-CTX) bind to Ca\textsuperscript{2+} channels and directly inhibit Ca\textsuperscript{2+} entry.

Increasingly, more α-conotoxins with this unique GABA\textsubscript{B}R-dependent VGCC inhibiting mechanism are being identified that show promise as novel analgesics (Table 1). Other α-conotoxins have also been identified that possess this GABA\textsubscript{B}R-dependent VGCC inhibitory mechanism, such as PeIA and AuIB [84,85]. Although the nAChR targets of these other conotoxins vary (PeIA inhibits α9α10, α3β2, α6/α3β2β3 [86] and AuIB inhibits α3β4 [87]), the common VGCC inhibiting mechanism is proposed to confer analgesic properties to both [54,88]. AuIB has been shown to be analgesic, while PeIA remains to be tested [57,58]. The inhibition of their respective nicotinic subunits may also contribute to their analgesia; however, the diversity of nAChR-subtypes inhibited by this group of α-conotoxins suggests that the inhibition of VGCCs via GABA\textsubscript{B}Rs is likely to be the primary mechanism of analgesia.

8. Conclusions

The discovery of analgesic α9α10-nAChR-inhibiting conotoxins highlighted the role of the α9α10-nAChR in pain for the first time. The presence of at least two mechanisms of action of Vc1.1 and RgIA has likely masked the dissociation between α9α10-nAChR-specific effects and other mechanisms. Inhibition of the α9α10-nAChR may be conferring an additional attenuating and restorative capacity to the conotoxins, alongside the acute analgesic effects via GABA\textsubscript{B}-dependent \textit{N}-type VGCC-inhibition [45,57]. \textit{In vivo} α9-nAChR KO experiments suggest that the inhibition of the α9α10-nAChR may have been erroneously attributed to be the mechanism of acute α-conotoxin analgesia.

As with all pharmacological studies, the assertions of the involvement of this receptor in pain are only as reliable as the selectivity, pharmacokinetics and pharmacodynamics of the compounds used. There is a significant risk of unknown functions of compounds being misattributed to the known targets. The non-analgesic Vc1.1 analogues, the α9-nAChR KO studies and the characterization of an alternative
mechanism of analgesia all support the notion that $\alpha_9\alpha_{10}$-nAChRs play a relatively minor role in pain perception and that conotoxins, such as Vc1.1 and RgIA, largely achieve their effects via $\alpha_9\alpha_{10}$-nAChR-independent mechanisms. While further characterization of the $\alpha_9\alpha_{10}$-nAChR in pain states is required, the evidence to date suggests that the involvement of the receptor in pain mechanisms and treatment has been overstated.

Acknowledgments

This work was supported by a National Health and Medical Research Council (NHMRC) Program Grant (MacDonald J. Christie). MacDonald J. Christie is supported by a NHMRC Senior Principal Research Fellowship.

Author Contributions

Sarasa A. Mohammadi and MacDonald J. Christie conceived of the review. Sarasa A. Mohammadi drafted and revised the manuscript with reviews and suggestions by MacDonald J. Christie.

Conflicts of Interest

The authors declare no conflict of interest.

References

1. Merskeu, H.; Bogduk, N. Part III: Pain terms, a current list with definitions and notes on usage. In Classification of Chronic Pain, 2nd ed.; IASP Press: Seattle, WA, USA, 1994; pp. 209–214.
2. Gureje, O.; Simon, G.E.; von Korff, M. A cross-national study of the course of persistent pain in primary care. Pain 2001, 92, 195–200.
3. Gaskin, D.J.; Richard, P. The economic costs of pain in the United States. J. Pain 2012, 13, 715–724.
4. Siddall, P.J.; Cousins, M.J. Persistent pain as a disease entity: Implications for clinical management. Anesth. Analg. 2004, 99, 510–520.
5. Tracey, I.; Bushnell, M.C. How neuroimaging studies have challenged us to rethink: Is chronic pain a disease? J. Pain 2009, 10, 1113–1120.
6. Katz, W.A.; Barkin, R.L. Dilemmas in chronic/persistent pain management. Am. J. Ther. 2008, 15, 256–264.
7. Levendoglu, F.; Ogun, C.O.; Ozerbil, O.; Ogun, T.C.; Ugurlu, H. Gabapentin is a first line drug for the treatment of neuropathic pain in spinal cord injury. Spine 2004, 29, 743–751.
8. Wiffen, P.J.; Derry, S.; Moore, R.A.; Aldington, D.; Cole, P.; Rice, A.S.C.; Lunn, M.P.T.; Hamunen, K.; Haanpaa, M.; Kalso, E.A. Antiepileptic drugs for neuropathic pain and fibromyalgia: An overview of Cochrane reviews. Cochrane Database Syst. Rev. 2013, 11, CD010567, doi:10.1002/14651858.CD010567.pub2.
9. Schroeder, C.I.; Lewis, R.J. $\omega$-conotoxins GVIA, MVIIA and CVID: SAR and clinical potential. Mar. Drugs 2006, 4, 193–214.
10. Knapp, O.; McArthur, J.R.; Adams, D.J. Conotoxins targeting neuronal voltage-gated sodium channel subtypes: Potential analgesics? Toxins 2012, 4, 1236–1260.
11. Bautista, D.M.; Siemens, J.; Glazer, J.M.; Tsuruda, P.R.; Basbaum, A.I.; Stucky, C.L.; Jordt, S.E.; Julius, D. The menthol receptor TRPM8 is the principal detector of environmental cold. *Nature* 2007, 448, 204–208.

12. Caterina, M.J.; Schumacher, M.A.; Tominaga, M.; Rosen, T.A.; Levine, J.D.; Julius, D. The capsaicin receptor: A heat-activated ion channel in the pain pathway. *Nature* 1997, 389, 816–824.

13. Lapointe, T.K.; Altier, C. The role of TRPA1 in visceral inflammation and pain. *Channels* 2011, 5, 525–529.

14. Lewis, R.J.; Dutertre, S.; Vetter, I.; Christie, M.J. Conus venom peptide pharmacology. *Pharmacol. Rev.* 2012, 64, 259–298.

15. Andrade, A.; Denome, S.; Jiang, Y.Q.; Marangoudakis, S.; Lipscombe, D. Opioid inhibition of N-type Ca\(^{2+}\) channels and spinal analgesia couple to alternative splicing. *Nat. Neurosci.* 2010, 13, 1249–1256.

16. Altier, C.; Dale, C.S.; Kisilevsky, A.E.; Chapman, K.; Castiglioni, A.J.; Matthews, E.A.; Evans, R.M.; Dickenson, A.H.; Lipscombe, D.; Vergnolle, N.; et al. Differential role of N-type calcium channel splice isoforms in pain. *J. Neurosci.* 2007, 27, 6363–6373.

17. Vetter, I.; Lewis, R.J. Therapeutic potential of cone snail venom peptides (conopeptides). *Curr. Top. Med. Chem.* 2012, 12, 1546–1552.

18. Millar, N.S.; Gotti, C. Diversity of vertebrate nicotinic acetylcholine receptors. *Neuropharmacology* 2009, 56, 237–246.

19. Lewis, R.J.; Nielsen, K.J.; Craik, D.J.; Loughnan, M.L.; Adams, D.A.; Sharpe, I.A.; Luchian, T.; Adams, D.J.; Bond, T.; Thomas, L.; et al. Novel \(\omega\)-conotoxins from *Conus catus* discriminate among neuronal calcium channel subtypes. *J. Biol. Chem.* 2000, 275, 35335–35344.

20. Zhang, M.M.; Green, B.R.; Catlin, P.; Fiedler, B.; Azam, L.; Chadwick, A.; Terlau, H.; McArthur, J.R.; French, R.J.; Gulyas, J.; et al. Structure/Function characterization of \(\mu\)-conotoxin KIIIA, an analgesic, nearly irreversible blocker of mammalian neuronal sodium channels. *J. Biol. Chem.* 2007, 282, 30699–30706.

21. Gotti, C.; Clementi, F. Neuronal nicotinic receptors: From structure to pathology. *Prog. Neurobiol.* 2004, 74, 363–396.

22. Elgoyhen, A.B.; Johnson, D.S.; Boulter, J.; Vetter, D.E.; Heinemann, S. \(\alpha\)9: An acetylcholine receptor with novel pharmacological properties expressed in rat cochlear hair-cells. *Cell* 1994, 79, 705–715.

23. Gotti, C.; Hanke, W.; Maury, K.; Moretti, M.; Ballivet, M.; Clementi, F.; Bertrand, D. Pharmacology and biophysical properties of \(\alpha\)7 and \(\alpha\)7-\(\alpha\)8 \(\alpha\)-bungarotoxin receptor subtypes immunopurified from the chick optic lobe. *Eur. J. Neurosci.* 1994, 6, 1281–1291.

24. Cepeda-Benito, A.; Reynoso, J.; McDaniel, E.H. Associative tolerance to nicotine analgesia in the rat: Tail-flick and hot-plate tests. *Exp. Clin. Psychopharmacol.* 1998, 6, 248–254.

25. Umana, I.C.; Daniele, C.A.; McGeehe, D.S. Neuronal nicotinic receptors as analgesic targets: It’s a winding road. *Biochem. Pharmacol.* 2013, 86, 1208–1214.

26. Gao, B.X.; Hierl, M.; Clarkin, K.; Juan, T.; Nguyen, H.; van der Valk, M.; Deng, H.; Guo, W.H.; Lehto, S.G.; Matson, D.; et al. Pharmacological effects of nonselective and subtype-selective nicotinic acetylcholine receptor agonists in animal models of persistent pain. *Pain* 2010, 149, 33–49.

27. Lang, P.M.; Burgstahler, R.; Sippel, W.; Irnich, D.; Schlotter-Weigel, B.; Grafe, P. Characterization of neuronal nicotinic acetylcholine receptors in the membrane of unmyelinated human C-fiber axons by *in vitro* studies. *J. Neurophysiol.* 2003, 90, 3295–3303.
28. Takeda, D.; Nakatsuka, T.; Papke, R.; Gu, J. Modulation of inhibitory synaptic activity by a non-α4β2, non-α7 subtype of nicotinic receptors in the substantia gelatinosa of adult rat spinal cord. *Pain* **2003**, *101*, 13–23.

29. Vincler, M.; Eisenach, J. Plasticity of spinal nicotinic acetylcholine receptors following spinal nerve ligation. *Neurosci. Res.* **2004**, *48*, 139–145.

30. Arneric, S.P.; Holladay, M.; Williams, M. Neuronal nicotinic receptors: A perspective on two decades of drug discovery research. *Biochem. Pharmacol.* **2007**, *74*, 1092–1101.

31. Hurst, R.; Rollema, H.; Bertrand, D. Nicotinic acetylcholine receptors: From basic science to therapeutics. *Pharmacol. Ther.* **2013**, *137*, 22–54.

32. Olivera, B.M.; Quik, M.; Vincler, M.; McIntosh, J.M. Subtype-selective conopeptides targeted to nicotinic receptors—Concerted discovery and biomedical applications. *Channels* **2008**, *2*, 143–152.

33. Arias, H.R.; Blanton, M.P. α-Conotoxins. *Int. J. Biochem. Cell Biol.* **2000**, *32*, 1017–1028.

34. Jin, A.H.; Vetter, I.; Dutertre, S.; Abraham, N.; Emidio, N.B.; Inserra, M.; Murali, S.S.; Christie, M.J.; Alewood, P.F.; Lewis, R.J. MrIC, a novel α-conotoxin agonist in the presence of PNU at endogenous α7 nicotinic acetylcholine receptors. *Biochemistry* **2014**, *53*, 1–3.

35. Dutton, J.L.; Craik, D.J. α-Conotoxins: Nicotinic acetylcholine receptor antagonists as pharmacological tools and potential drug leads. *Curr. Med. Chem.* **2001**, *8*, 327–344.

36. Lebbe, E.K.M.; Peigneur, S.; Wijesekara, I.; Tytgat, J. Conotoxins targeting nicotinic acetylcholine receptors: An overview. *Mar. Drugs* **2014**, *12*, 2970–3004.

37. Clark, R.J.; Fischer, H.; Nevin, S.T.; Adams, D.J.; Craik, D.J. The synthesis, structural characterization, and receptor specificity of the α-conotoxin Vc1.1. *J. Biol. Chem.* **2006**, *281*, 23254–23263.

38. Vincler, M.; Wittenauer, S.; Parker, R.; Ellison, M.; Olivera, B.M.; McIntosh, J.M. Molecular mechanism for analgesia involving specific antagonism of α9α10 nicotinic acetylcholine receptors. *Proc. Natl. Acad. Sci. USA* **2006**, *103*, 17880–17884.

39. Ellison, M.; Haberlandt, C.; Gomez-Casati, M.E.; Watkins, M.; Elgoyhen, A.B.; McIntosh, J.M.; Olivera, B.M. α-RgIA: A novel conotoxin that specifically and potently blocks the α9α10 nAChR. *Biochemistry* **2006**, *45*, 1511–1517.

40. Clark, R.J.; Jensen, J.; Nevin, S.T.; Callaghan, B.P.; Adams, D.J.; Craik, D.J. The engineering of an orally active conotoxin for the treatment of neuropathic pain. *Angew. Chem. Int. Ed.* **2010**, *49*, 6545–6548.

41. Halai, R.; Caaghan, B.; Daly, N.L.; Clark, R.J.; Adams, D.J.; Craik, D.J. Effects of cyclization on stability, structure, and activity of alpha-Conotoxin RgIA at the alpha 9 alpha 10 nicotinic acetylcholine receptor and GABA(B) receptor. *J. Med. Chem.* **2011**, *54*, 6984–6992.

42. van Lierop, B.J.; Robinson, S.D.; Kompella, S.N.; Belgi, A.; McArthur, J.R.; Hung, A.; MacRaild, C.A.; Adams, D.J.; Norton, R.S.; Robinson, A.J. Dicarba α-conotoxin Vc1.1 analogues with differential selectivity for nicotinic acetylcholine and GABA(B) receptors. *ACS Chem. Biol.* **2013**, *8*, 1815–1821.

43. Chhabra, S.; Belgi, A.; Bartels, P.; van Lierop, B.J.; Robinson, S.D.; Kompella, S.N.; Hung, A.; Callaghan, B.P.; Adams, D.J.; Robinson, A.J. Dicarba analogues of α-conotoxin RgIA. Structure, stability, and activity at potential pain targets. *J. Med. Chem.* **2014**, *57*, 9933–9944.

44. Pérez, E.G.; Cassels, B.K.; Zapata-Torres, G. Molecular modeling of the α9α10 nicotinic acetylcholine receptor subtype. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 251–254.
45. Callaghan, B.; Adams, D.J. Analgesic α-conotoxins Vc1.1 and Rg1A inhibit N-type calcium channels in sensory neurons of α9 nicotinic receptor knockout mice. *Channels* **2010**, *4*, 51–54.

46. Haberberger, R.V.; Bernardini, N.; Kress, M.; Hartmann, P.; Lips, K.S.; Kummer, W. Nicotinic acetylcholine receptor subtypes in nociceptive dorsal root ganglion neurons of the adult rat. *Auton. Neurosci.* **2004**, *113*, 32–42.

47. Lips, K.S.; Pfeil, U.; Kummer, W. Coexpression of α9 and α10 nicotinic acetylcholine receptors in rat dorsal root ganglion neurons. *Neuroscience* **2002**, *115*, 1–5.

48. Elgoyhen, A.B.; Vetter, D.E.; Katz, E.; Rothlin, C.V.; Heinemann, S.F.; Boulter, J. α10: A determinant of nicotinic cholinergic receptor function in mammalian vestibular and cochlear mechanosensory hair cells. *Proc. Natl. Acad. Sci. USA* **2001**, *98*, 3501–3506.

49. Vetter, D.E.; Liberman, M.C.; Mann, J.; Barhanin, J.; Boulter, J.; Brown, M.C.; Saffiote-Kolman, J.; Heinemann, S.F.; Elgoyhen, A.B. Role of α9 nicotinic ACh receptor subunits in the development and function of cochlear efferent innervation. *Neuron* **2001**, *23*, 93–103.

50. Satkunanathan, N.; Livett, B.; Gayler, K.; Sandall, D.; Down, J.; Khalil, Z. Alpha-conotoxin Vc1.1 alleviates neuropathic pain and accelerates functional recovery of injured neurones. *Brain Res.* **2005**, *1059*, 149–158.

51. Azam, L.; McIntosh, J.M. Molecular basis for the differential sensitivity of rat and human α9α10 nAChRs to α-conotoxin Rg1A. *J. Neurochem.* **2012**, *122*, 1137–1144.

52. Metabolic discontinues clinical trial programme for neuropathic pain drug, ACV1. Available online: http://www.asx.com.au/asxpdf/20070814/pdf/313yjgpf7ji4lg.pdf (accessed on 1 December 2014).

53. McIntosh, J.M.; Absalom, N.; Chebib, M.; Elgoyhen, A.B.; Vincler, M. Alpha9 nicotinic acetylcholine receptors and the treatment of pain. *Biochem. Pharmacol.* **2009**, *78*, 693–702.

54. Adams, D.J.; Callaghan, B.; Berecki, G. Analgesic conotoxins: Block and G protein-coupled receptor modulation of N-type (Cav.2.2) calcium channels. *Br. J. Pharmacol.* **2012**, *166*, 486–500.

55. Mannelli, L.D.C.; Cinci, L.; Micheli, L.; Zanardelli, M.; Pacini, A.; McIntosh, M.J.; Ghelardini, C. α-Conotoxin Rg1A protects against the development of nerve injury-induced chronic pain and prevents both neuronal and glial derangement. *Pain* **2014**, *155*, 1986–1995.

56. Nevin, S.T.; Clark, R.J.; Klimis, H.; Christie, M.J.; Craik, D.J.; Adams, D.J. Are α9α10 nicotinic acetylcholine receptors a pain target for α-conotoxins? *Mol. Pharmacol.* **2007**, *72*, 1406–1410.

57. Klimis, H.; Adams, D.J.; Callaghan, B.; Nevin, S.; Alewood, P.F.; Vaughan, C.W.; Mozart, C.A.; Christie, M.J. A novel mechanism of inhibition of high-voltage activated calcium channels by α-conotoxins contributes to relief of nerve injury-induced neuropathic pain. *Pain* **2011**, *152*, 259–266.

58. Napier, I.A.; Klimis, H.; Rycroft, B.K.; Jin, A.H.; Alewood, P.F.; Motin, L.; Adams, D.J.; Christie, M.J. Intrathecal α-conotoxins Vc1.1, Au1B and MII acting on distinct nicotinic receptor subtypes reverse signs of neuropathic pain. *Neuropsychopharmacology* **2012**, *62*, 2202–2207.

59. Mohammadi, S.; Christie, M.J. α9-nicotinic acetylcholine receptors contribute to the maintenance of chronic mechanical hyperalgesia, but not thermal or mechanical allodynia. *Mol. Pain* **2014**, *10*, 64, doi:10.1186/1744-8069-10-64.

60. Livett, B.; Khalil, Z.; Gayler, K.; Down, J. Alpha Conotoxin Peptides with Analgesic Properties. Patent number WO 02/079236 A1, filed 28 March 2002 and issued 10 October 2002.
Toxins 2015, 7

61. Sandall, D.W.; Satkunanathan, N.; Keays, D.A.; Polidano, M.A.; Liping, X.; Pham, V.; Down, J.G.; Khalil, Z.; Livett, B.G.; Gayler, K.R. A novel α-conotoxin identified by gene sequencing is active in suppressing the vascular response to selective stimulation of sensory nerves in vivo. *Biochemistry* 2003, 42, 6904–6911.

62. Mohammadi, S.; Christie, M.J. The University of Sydney, NSW, Australia, Unpublished work, 2015.

63. Vincler, M.; McIntosh, J.M. Targeting the α9α10 nicotinic acetylcholine receptor to treat severe pain. *Expert Opin. Ther. Targets* 2007, 11, 891–897.

64. Holtman, J.R.; Dwoskin, L.P.; Dowell, C.; Wala, E.P.; Zhang, Z.F.; Crooks, P.A.; McIntosh, J.M. The novel small molecule α9α10 nicotinic acetylcholine receptor antagonist ZZ-204G is analgesic. *Eur. J. Pharmacol.* 2011, 670, 500–508.

65. Wala, E.P.; Crooks, P.A.; McIntosh, J.M.; Holtman, J.R. Novel small molecule α9α10 nicotinic receptor antagonist prevents and reverses chemotherapy-evoked neuropathic pain in rats. *Anesth. Analg.* 2012, 115, 713–720.

66. Kawashima, K.; Fujii, T. Expression of non-neuronal acetylcholine in lymphocytes and its contribution to the regulation of immune function. *Front. Biosci.* 2004, 9, 2063–2085.

67. Rinner, I.; Felsner, P.; Falus, A.; Skreiner, E.; Kukulansky, T.; Globerson, A.; Hirokawa, K.; Schauenstein, K. Cholinergic signals to and from the immune-system. *Immunol. Lett.* 1995, 44, 217–220.

68. Sato, K.Z.; Fujii, T.; Watanabe, Y.; Yamada, S.; Ando, T.; Kazuko, F.; Kawashima, K. Diversity of mRNA expression for muscarinic acetylcholine receptor subtypes and neuronal nicotinic acetylcholine receptor subunits in human mononuclear leukocytes and leukemic cell lines. *Neurosci. Lett.* 1999, 266, 17–20.

69. Peng, H.S.; Ferris, R.L.; Matthews, T.; Hiel, H.; Lopez-Albaitero, A.; Lustig, L.R. Characterization of the human nicotinic acetylcholine receptor subunit alpha (α) 9 (CHRNA9) and alpha (α) 10 (CHRNA10) in lymphocytes. *Life Sci.* 2004, 76, 263–280.

70. Genzen, J.R.; van Cleve, W.; McGehee, D.S. Dorsal root ganglion neurons express multiple nicotinic acetylcholine receptor subtypes. *J. Neurophysiol.* 2001, 86, 1773–1782.

71. Dubé, G.R.; Kohlhaas, K.L.; Rueter, L.E.; Surowy, C.S.; Meyer, M.D.; Briggs, C.A. Loss of functional neuronal nicotinic receptors in dorsal root ganglion neurons in a rat model of neuropathic pain. *Neurosci. Lett.* 2005, 376, 29–34.

72. Damaj, M.I.; Fei-Yin, M.; Dukat, M.; Glassco, W.; Glennon, R.A.; Martin, B.R. Antinociceptive responses to nicotinic acetylcholine receptor ligands after systemic and intrathecal administration in mice. *J. Pharmacol. Exp. Ther.* 1998, 284, 1058–1065.

73. Kong, J.H.; Adelman, J.P.; Fuchs, P.A. Expression of the SK2 calcium-activated potassium channel is required for cholinergic function in mouse cochlear hair cells. *J. Physiol.* 2008, 586, 5471–5485.

74. Zhou, T.; Wang, Y.; Guo, C.K.; Zhang, W.J.; Yu, H.; Zhang, K.; Kong, W.J. Two distinct channels mediated by m2mAChR and α9nAChR co-exist in type II vestibular hair cells of guinea pig. *Int. J. Mol. Sci.* 2013, 14, 8818–8831.

75. Halai, R.; Clark, R.J.; Nevin, S.T.; Jensen, J.E.; Adams, D.J.; Craik, D.J. Scanning mutagenesis of α-conotoxin Vc1.1 reveals residues crucial for activity at the α9α10 nicotinic acetylcholine receptor. *J. Biol. Chem.* 2009, 284, 20275–20284.
76. Mesnage, B.; Gaillard, S.; Godin, A.G.; Rodeau, J.L.; Hammer, M.; von Engelhardt, J.; Wiseman, P.W.; de Koninck, Y.; Schlichter, R.; Cordero-Erausquin, M. Morphological and functional characterization of cholinergic interneurons in the dorsal horn of the mouse spinal cord. *J. Comp. Neurol.* **2011**, *519*, 3139–3158.

77. Matsumoto, M.; Xie, W.J.; Inoue, M.; Ueda, H. Evidence for the tonic inhibition of spinal pain by nicotinic cholinergic transmission through primary afferents. *Mol. Pain* **2007**, *3*, 41.

78. Dussor, G.O.; Jones, D.J.; Hulsebosch, C.E.; Edell, T.A.; Flores, C.M. The effects of chemical or surgical deafferentation on H-3-acetylcholine release from rat spinal cord. *Neuroscience* **2005**, *135*, 1269–1276.

79. Grando, S.A.; Kist, D.A.; Qi, M.; Dahl, M.V. Human keratinocytes synthesize, secrete, and degrade acetylcholine. *J. Investig. Dermatol.* **1993**, *101*, 32–36.

80. Kawashima, K.; Fujii, T. Basic and clinical aspects of non-neuronal acetylcholine: Overview of non-neuronal cholinergic systems and their biological significance. *J. Pharmacol. Sci.* **2008**, *106*, 167–173.

81. Mihovilovic, M.; Denning, S.; Mai, Y.; Fisher, C.M.; Whichard, L.P.; Patel, D.D.; Roses, A.D. Thymocytes and cultured thymic epithelial cells express transcripts encoding α-3, α-5, and β-4 subunits of neuronal nicotinic acetylcholine receptors—Preferential transcription of the α-3 and β-4 genes by immature CD4+8+ thymocytes and evidence for response to nicotine in thymocytes. In *Myasthenia Gravis and Related Diseases: Disorders of the Neuromuscular Junction*; Richman, D.P., Ed.; New York Acad Sciences: New York, NY, USA, 1998; Volume 841, pp. 388–392.

82. Kawashima, K.; Yoshikawa, K.; Fujii, Y.X.; Moriwaki, Y.; Misawa, H. Expression and function of genes encoding cholinergic components in murine immune cells. *Life Sci.* **2007**, *80*, 2314–2319.

83. Callaghan, B.; Haythornthwaite, A.; Berecki, G.; Clark, R.J.; Craik, D.J.; Adams, D.J. Analgesic α-conotoxins Vc1.1 and Rg1A inhibit N-type calcium channels in rat sensory neurons via GABA(B) receptor activation. *J. Neurosci.* **2008**, *28*, 10943–10951.

84. Grishin, A.A.; Cuny, H.; Hung, A.; Clark, R.J.; Brust, A.; Akondi, K.; Alewood, P.F.; Craik, D.J.; Adams, D.J. Identifying key amino acid residues that affect α-conotoxin AuIB inhibition of α3β4 nicotinic acetylcholine receptors. *J. Biol. Chem.* **2013**, *288*, 34428–34442.

85. Daly, N.L.; Callaghan, B.; Clark, R.J.; Nevin, S.T.; Adams, D.J.; Craik, D.J. Structure and activity of α-conotoxin PeIA at nicotinic acetylcholine receptor subtypes and GABA(B) receptor-coupled N-type calcium channels. *J. Biol. Chem.* **2011**, *286*, 10233–10237.

86. McIntosh, J.M.; Plazas, P.V.; Watkins, M.; Gomez-Casati, M.E.; Olivera, B.M.; Elgoyhen, A.B. A novel α-conotoxin, PeA, cloned from *Conus pergrandis*, discriminates between rat α9α10 and α7 nicotinic cholinergic receptors. *J. Biol. Chem.* **2005**, *280*, 30107–30112.

87. Luo, L.; Bennett, T.; Jung, H.H.; Ryan, A.F. Developmental expression of α9 acetylcholine receptor mRNA in the rat cochlea and vestibular inner ear. *J. Comp. Neurol.* **1998**, *393*, 320–331.

88. Adams, D.J.; Berecki, G. Mechanisms of conotoxin inhibition of N-type (Ca.2.2) calcium channels. *Biochim. Biophys. Acta* **2013**, *1828*, 1619–1628.

© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).